Postmenopausal osteoporosis results from defective bone remodeling stemming from estrogen (E2) deficiency. We have recently reported that bone loss during E2 deficiency is driven principally by upregulated T cell-derived cytokine secretion including the key osteoclastogenic cytokines, Receptor-activator of NFkB Ligand (RANKL) and Tumor necrosis Factor alpha (TNF). A key event in inducing T cell activation and cytokine secretion is the upregulation of IL-7 production, a consequence of estrogen deficiency. We have recently reported that inhibiting the elevated levels of IL-7 induced by ovariectomy (ovx) in mice using a neutralizing antibody, is efficacious in preventing ovx-induced bone loss in mice in vivo. This suggests that IL-7 neutralization may be a novel means to prevent and treat osteoporosis. However, despite the success of this experiment, long-term therapeutic treatment with antibodies in humans often lead to serious clinical complications and poor long-term efficacy. In order to overcome the limitations of antibody-based therapies, we now propose a novel strategy to neutralize IL-7 in vivo and ameliorate bone loss in postmenopausal osteoporosis. This strategy involves the design of a novel peptide based therapeutic agent comprising the soluble extracellular ligand-binding domain of the mouse IL-7 receptor alpha (slL-7Ralpha). To extend in vivo half-life this peptide will be expressed as a fusion protein with the human IgG1-Fc region (slL-7Ralpha-Fc). We hypothesize that this agent will function in vivo as a soluble IL-7 decoy receptor and prevent bone loss during E2 deficiency, by neutralizing excess IL-7. We propose two Specific Aims to further investigate our hypothesis:
Specific Aim 1 : To demonstrate that a soluble IL-7 decoy receptor is an efficacious therapeutic adjunct in preventing estrogen deficiency-induced bone loss in vivo. This will be achieved by injecting purified recombinant slL-7Ralpha-Fc into mice following ovx and examining physical, biochemical and histomorphometric indices of bone turnover following ovariectomy. Long-term stability and biological half-life of slL-7Ralpha-Fc will be evaluated by measuring levels of free IL-7 and slL-7Ralpha-Fc concentrations in blood serum as a function of time.
Specific Aim 2 : To demonstrate the feasibility of preserving bone mass following estrogen deficiency by expressing a soluble IL-7 decoy receptor in vivo, using a gene transfer approach.
This Specific Aim will be achieved by the introduction into ovx mice of a mammalian expression vector encoding slL-7Ralpha-Fc by application of two different gene transfer procedures, intramuscular injection targeting skeletal muscle and hydrodynamic injection targeting the liver.
These Specific Aims will demonstrate two important """"""""Proofs of Principle"""""""": (1) a novel therapeutic agent slL-7Ralpha-Fc, is an efficacious therapy for the prevention of bone loss following estrogen deficiency. (2) Gene transfer is an effective mechanism for introducing and expressing slL-7Ralpha-Fc in vivo.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Exploratory/Developmental Grants (R21)
Project #
1R21DK067389-01
Application #
6765563
Study Section
Skeletal Biology Structure and Regeneration Study Section (SBSR)
Program Officer
Malozowski, Saul N
Project Start
2004-03-01
Project End
2006-02-28
Budget Start
2004-03-01
Budget End
2005-02-28
Support Year
1
Fiscal Year
2004
Total Cost
$153,000
Indirect Cost
Name
Emory University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
066469933
City
Atlanta
State
GA
Country
United States
Zip Code
30322
Gao, Yuhao; Wu, Xiaojun; Terauchi, Masakazu et al. (2008) T cells potentiate PTH-induced cortical bone loss through CD40L signaling. Cell Metab 8:132-45
Li, Yan; Li, Aimin; Strait, Karen et al. (2007) Endogenous TNFalpha lowers maximum peak bone mass and inhibits osteoblastic Smad activation through NF-kappaB. J Bone Miner Res 22:646-55
Li, Yan; Li, Aimin; Yang, Xiaoying et al. (2007) Ovariectomy-induced bone loss occurs independently of B cells. J Cell Biochem 100:1370-5
Li, Yan; Toraldo, Gianluca; Li, Aimin et al. (2007) B cells and T cells are critical for the preservation of bone homeostasis and attainment of peak bone mass in vivo. Blood 109:3839-48
Gao, Yuhao; Grassi, Francesco; Ryan, Michaela Robbie et al. (2007) IFN-gamma stimulates osteoclast formation and bone loss in vivo via antigen-driven T cell activation. J Clin Invest 117:122-32
Grassi, F; Fan, X; Rahnert, J et al. (2006) Bone re/modeling is more dynamic in the endothelial nitric oxide synthase(-/-) mouse. Endocrinology 147:4392-9
Weitzmann, M Neale; Pacifici, Roberto (2006) Estrogen deficiency and bone loss: an inflammatory tale. J Clin Invest 116:1186-94
Ryan, Michaela Robbie; Shepherd, Rebecca; Leavey, Jennifer K et al. (2005) An IL-7-dependent rebound in thymic T cell output contributes to the bone loss induced by estrogen deficiency. Proc Natl Acad Sci U S A 102:16735-40